Rationale for the Early Use of Sodium-Glucose Cotransporter-2 Inhibitors in Patients with Type 2 Diabetes
Crossref DOI link: https://doi.org/10.1007/s12325-019-01054-w
Published Online: 2019-08-23
Published Print: 2019-10
Update policy: https://doi.org/10.1007/springer_crossmark_policy
Handelsman, Yehuda http://orcid.org/0000-0001-7830-0247
Funding for this research was provided by:
AstraZeneca
Article History
Received: 7 June 2019
First Online: 23 August 2019